LSA
DNLI icon

Leonteq Securities AG’s Denali Therapeutics DNLI Stock Holding History

Leonteq Securities AG’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-50
Closed -$1.39K – 1236
2022
Q4 		$1.39K Sell
50
-40
-44% -$1.19K ﹤0.01% 1209
2022
Q3 		$2.76K Sell
90
-13
-13% -$423 ﹤0.01% 1170
2022
Q2 		$3.03K Sell
103
-34
-25% -$891 ﹤0.01% 1179
2022
Q1 		$4.41K Buy
137
+39
+40% +$1.34K ﹤0.01% 1173
2021
Q4 		$4.37K Buy
98
+33
+51% +$1.56K ﹤0.01% 1192
2021
Q3 		$3.28K Buy
+65
New +$3.66K ﹤0.01% 1084

Other funds holding DNLI

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $29.7B AUM 13.98% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return